Abstract: Compounds having the formula ##STR1## and the pharmaceutically acceptable salts, esters, amides and prodrugs thereof, wherein one of R.sup.104 and R.sup.105 is hydrogen, and the other of R.sup.104 and R.sup.105 is a radical having the formula ##STR2## as well as pharmaceutically compositions containing such compounds and methods of immunomodulative therapy utilizing the same.

Abstract: Compounds having the formula ##STR1## and pharmaceutically acceptable salts, esters, amides and prodrugs thereof, wherein one of R.sup.104 and R.sup.105 is hydrogen, and the other of R.sup.104 and R.sup.105 is a group having the formula ##STR2## as well as pharmaceutically compositions containing such compounds and methods of immunomodulative therapy utilizing the same.

Abstract: Immunomodulatory macrocyclic compounds having the formula: ##STR1## and pharmaceutically acceptable salts, esters, amides and prodrugs thereof,where R.sup.8 and R.sup.9 are selected such that one of R.sup.8 and R.sup.9 is hydrogen and the other is --S(O).sub.s --heterocyclic,as well as pharmaceutical compositions containing such compounds and therapeutic methods of their use.

Abstract: A solid pharmaceutical composition is disclosed which comprises a pharmaceutically acceptable adsorbent or a mixture of pharmaceutically acceptable adsorbents to which is adsorbed a mixture of (1) a pharmaceutically acceptable organic solvent or a mixture of pharmaceutically acceptable organic solvents, (2) an HIV protease inhibiting compound and (3) one or more pharmaceutically acceptable acids. The solid composition can optionally be encapsulated in a hard gelatin capsule.

Abstract: A retroviral protease inhibiting compound of the formula A--X--B is disclosed. Also disclosed are a composition and method for inhibiting a retroviral protease and for treating an HIV infection. Also disclosed are processes and intermediates useful for the preparation of the retroviral protease inhibitors.

Abstract: A retroviral protease inhibiting compound of the formula: ##STR1## is disclosed.

Abstract: A retroviral protease inhibiting compound of the formulaA--X--Bor a pharmaceutically acceptable salt, prodrug or ester thereof, wherein X is a linking group;A is(1) substituted amino,(2) substituted carbonyl,(3) functionalized imino,(4) functionalized alkyl,(5) functionalized acyl,(6) functionalized heterocyclic or(7) functionalized (heterocyclic)alkyl; andB is(1) substituted carbonyl independently defined as herein,(2) substituted amino independently defined as herein,(3) functionalized imino independently defined as herein,(4) functionalized alkyl independently defined as herein,(5) functionalized acyl independently defined as herein,(6) functionalized heterocyclic independently defined as herein or(7) functionalized (heterocyclic)alkyl independently defined as herein.

Abstract: Intermediates and processes are disclosed which are useful for the preparation of a substantially pure compound of the formula: ##STR1## wherein R.sub.6 and R.sub.7 are each hydrogen or R.sub.6 and R.sub.7 are independently selected from ##STR2## wherein R.sub.a and R.sub.b are independently selected from hydrogen, loweralkyl and phenyl and R.sub.c, R.sub.d and R.sub.e are independently selected from hydrogen, loweralkyl, trifluoromethyl, alkoxy, halo and phenyl; and ##STR3## wherein the naphthyl ring is unsubstituted or substituted with one, two or three substitutents independently selected from loweralkyl, trifluoromethyl, alkoxy and halo; orR.sub.6 is as defined above and R.sub.7 is R.sub.7a OC(O)-- wherein R.sub.7a is loweralkyl or benzyl; orR.sub.6 and R.sub.7 taken together with the nitrogen atom to which they are bonded are ##STR4## wherein R.sub.f, R.sub.g, R.sub.h and R.sub.i are independently selected from hydrogen, loweralkyl, alkoxy, halogen and trifluoromethyl and R.sub.

Abstract: Intermediates and processes are disclosed which are useful for the preparation of a substantially pure compound of the formula: ##STR1## wherein R.sub.6 and R.sub.7 are each hydrogen or R.sub.6 and R.sub.7 are independently selected from ##STR2## wherein R.sub.a and R.sub.b are independently selected from hydrogen, loweralkyl and phenyl and R.sub.c, R.sub.d and R.sub.e are independently selected from hydrogen, loweralkyl, trifluoromethyl, alkoxy, halo and phenyl; and ##STR3## wherein the naphthyl ring is unsubstituted or substituted with one, two or three substitutents independently selected from loweralkyl, trifluoromethyl, alkoxy and halo; orR.sub.6 is as defined above and R.sub.7 is R.sub.7a OC(O)- wherein R.sub.7a is loweralkyl or benzyl; orR.sub.6 and R.sub.7 taken together with the nitrogen atom to which they are bonded are ##STR4## wherein R.sub.f, R.sub.g, R.sub.h and R.sub.i are independently selected from hydrogen, loweralkyl, alkoxy, halogen and trifluoromethyl and R.sub.

Abstract: Intermediates and processes are disclosed which are useful for the preparation of a substantially pure compound of the formula: ##STR1## wherein R.sub.6 and R.sub.7 are each hydrogen or R.sub.6 and R.sub.7 are independently selected from ##STR2## wherein R.sub.a and R.sub.b are independently selected from hydrogen, loweralkyl and phenyl and R.sub.c, R.sub.d and R.sub.e are independently selected from hydrogen, loweralkyl, trifluoromethyl, alkoxy, halo and phenyl; and ##STR3## wherein the naphthyl ring is unsubstituted or substituted with one, two or three substitutents independently selected from loweralkyl, trifluoromethyl, alkoxy and halo; orR.sub.6 is as defined above and R.sub.7 is R.sub.7a OC(O)-- wherein R7a is loweralkyl or benzyl; orR.sub.6 and R.sub.7 taken together with the nitrogen atom to which they are bonded are ##STR4## wherein R.sub.f, R.sub.g, R.sub.h and R.sub.i are independently selected from hydrogen, loweralkyl, alkoxy, halogen and trifluoromethyl and R.sub.

Abstract: A process is disclosed for the preparation of a substituted diaminoalcohol of the formula: ##STR1##

Abstract: A retroviral protease inhibiting compound of the formula A--X--B is disclosed. Also disclosed are a composition and method for inhibiting a retroviral protease and for treating an HIV infection. Also disclosed are processes and intermediates useful for the preparation Of the retroviral protease inhibitors.

Abstract: Immunomodulatory macrocyclic compounds having the formula ##STR1## and pharmaceutically acceptable salts, esters, amides and prodrugs thereof, wherein one of R.sup.107, R.sup.108, R.sup.109 and R.sup.110 is a radical having the formula ##STR2## as well as pharmaceutically compositions containing such compounds and methods of immunomodulatory therapy utilizing the same.

Abstract: A substantially pure compound of formula: ##STR1## wherein R.sub.6 and R.sub.7 are independently selected from ##STR2## wherein R.sub.a and R.sub.b are independently selected from hydrogen, loweralkyl and phenyl and R.sub.c, R.sub.d and R.sub.e are independently selected from hydrogen, loweralkyl, trifluoromethyl, alkoxy, halo and phenyl; and ##STR3## wherein the naphthyl ring is unsubstituted or substituted with one, two or three substitutents independently selected from loweralkyl, trifluoromethyl, alkoxy and halo; orR.sub.6 is as defined above and R.sub.7 is R.sub.7a OC(O)-- wherein R.sub.7a is loweralkyl; orR.sub.6 and R.sub.7 taken together with the nitrogen atom to which they are bonded are ##STR4## wherein R.sub.f, R.sub.g, R.sub.h and R.sub.l are independently selected from hydrogen, loweralkyl, alkoxy, halogen and trifluoromethyl; andR.sub.g is hydrogen, loweralkyl or benzyl; or an acid addition salt thereof.

Abstract: Compounds having the formula ##STR1## and the pharmaceutically acceptable salts, esters, amides and prodrugs thereof, wherein one of R.sup.104 and R.sup.105 is hydrogen, and the other of R.sup.104 and R.sup.105 is a radical having the formula ##STR2## as well as pharmaceutically compositions containing such compounds and methods of immunomodulative therapy utilizing the same.

Abstract: A process is disclosed for the preparation of a substituted diaminoalcohol of the formula: ##STR1##

Abstract: A retroviral protease inhibiting compound of the formula: ##STR1## is disclosed.

Abstract: A retroviral protease inhibiting compound of the formula: ##STR1## is disclosed.

Abstract: Immunomodulatory macrocyclic compounds having the formula: ##STR1## and the pharmaceutically acceptable salts, esters, amides and prodrugs thereof, wherein R.sup.8 and R.sup.9 are selected such that one of R.sup.8 and R.sup.9 is hydrogen, and the other is chosen from the group consisting of:(1) --OC(.dbd.NR.sup.10)-NHR.sup.10 ;(2) --OC(.dbd.O)-R.sup.11 ; and(3) --OC(.dbd.O)-NR.sup.12 R.sup.13 ;(4) --OC(.dbd.O)-N(OR.sup.14)R.sup.12 ;(5) --OC(.dbd.O)-NHNR.sup.12 R.sup.13 ;(6) --OC(.dbd.O)-NH-NHC(.dbd.O)-NR.sup.12 R.sup.13 ;(7) --OC(.dbd.O)-NH-NHS(O).sub.2 --NR.sup.12 R.sup.13 ; and(8) --OC(.dbd.O)-NH-NHC(.dbd.NR.sup.21 )-NR.sup.12 R.sup.13. as well as pharmaceutical compositions containing such compounds and methods for their use in immunosuppressive, antimicrobial, antifungal, antiviral, antiinflammatory and antiproliferative therapy.

Abstract: Compounds having the formula ##STR1## and the pharmaceutically acceptable salts, esters, amides and prodrugs thereof, wherein one of R.sup.104 and R.sup.105 is hydrogen, and the other of R.sup.104 and R.sup.105 is a radical having the formula ##STR2## as well as pharmaceutically compositions containing such compounds and methods of immunomodulative therapy utilizing the same.